Julio de la Torre-Montero

Prof. Julio de la Torre-Montero

Health Sciences, Comillas Pontifical University, Madrid, Spain
orcid
Comillas Pontifical University, Madrid, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DCDaniela Caronia
Daniela Caronia
MMMiguel Martin
Miguel Martin
JSJavier Sastre
Javier Sastre
Julio de la Torre-MonteroJulio de la Torre-Montero
Julio de la Torre-Montero
JGJosé Ángel García-Saénz
José Ángel García-Saénz
Anna Gonzalez-NeiraAnna Gonzalez-Neira
Anna Gonzalez-Neira
Purpose: Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer. We investigated the association between grade 3 HFS and genetic variations in genes involved in capecitabine metabolism. Experimental Design: We genotyped a total of 13 polymorphisms in the carboxylesterase 2 (CES2) gene, the cytidine deaminase (CDD) gene, the thymidine phosphorylase (TP) gene, the thymidylate synthase (TS) gene, and the dihydropyrimidine dehydrogenase (DPD) gene in 130 patients treated with capecitabine. We correlated these polymorphisms with susceptibility to HFS. Results: We found an association of HFS appearance with rs532545 located in the promoter region of CDD (OR = 2.02, 95% CI = 1.02–3.99, P = 0.039). Because we found no association between the rs532545 genotype and CDD mRNA expression in Epstein-Barr virus lymphoblastoid cells, we explored additional genetic variations across the CDD promoter. We found an insertion, rs3215400, in linkage disequilibrium with rs532545 (D′ = 0.92), which was more clearly associated with HFS (OR = 0.51, 95% CI = 0.27–0.95, P = 0.028) in patients and with total CDD gene expression (P = 0.004) in lymphoblastoid cells. In silico analysis suggested that this insertion might create a binding site for the transcriptional regulator E2F. Using a SNaPshot assay in lymphoblastoid cells, we observed a 5.7-fold increased allele-specific mRNA expression from the deleted allele. Conclusions: The deleted allele of rs3215400 shows an increased allele-specific expression and is significantly associated with an increased risk of capecitabine-induced HFS. Clin Cancer Res; 17(7); 2006–13. ©2011 AACR.

6 April 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MMM. Martin
M. Martin
ARAtocha Romero
Atocha Romero
MCMaggie Cheang
Maggie Cheang
JGJ. A. López García-Asenjo
J. A. López García-Asenjo
JGJosé Ángel García-Saénz
José Ángel García-Saénz
CPCharles M Perou
Charles M Perou

1 June 2021 in ESMO Open
Verified
Journal Article
Open access
MAM. Amador
M. Amador
XMX. Matias-Guiu
X. Matias-Guiu
GSG. Sancho-Pardo
G. Sancho-Pardo
JMJ. Contreras Martinez
J. Contreras Martinez
Julio de la Torre-MonteroJulio de la Torre-Montero
Julio de la Torre-Montero
LPL. Paz-Ares
L. Paz-Ares
Studies evaluating the effects of the COVID-19 pandemic on public healthcare systems are limited, particularly in cancer management. As no such studies have been carried out in Spain, our objective is to describe and quantify the impact of the COVID-19 pandemic on cancer patients in Spanish hospitals during the first wave of the pandemic. This retrospective, multicenter, nationwide study collected information from hospital departments treating oncology patients. An electronic questionnaire comparing outcomes and management of oncohematological patients for the March-June 2019 and March-June 2020 periods was used. Information from 78 departments (36 tertiary hospitals) was analyzed. Forty-four departments implemented adapted protocols during March 2020. Most of these (n = 38/44; 86.4%) carried out COVID-19 triage, while 26 of 44 (59.1%) carried out onsite polymerase chain reaction tests for clinically suspected cases. A shift from in-person to telephone visits was observed in 43 of 44 (97.7%) departments. Comparing the March-June 2019 and March-June 2020 periods, the number of new patients decreased by 20.8% (from 160.2 to 126.4). Decreases were also seen in the mean number of total (2858.2 versus 1686.1) and cancer (465.5 versus 367.2) biopsies, as well as the mean number of bone marrow biopsies (30.5 versus 18.6). Concerning the number of patients visiting specific cancer care departments, a decrease from 2019 to 2020 was seen for mean number of chemotherapy treatments (712.7 versus 643.8) and radiation therapy (2169.9 versus 2139.9). Finally, a reduction from 2019 to 2020 of 12.9% (from 8.6 to 7.4) in the mean number of patients included in clinical trials was noted. This study provides the first comprehensive data concerning the impact of COVID-19 on cancer care in Spain. The pandemic caused a 20.8% decrease in newly diagnosed patients, which may impact future outcomes. Measures must be taken to ensure cancer management receives priority in times of healthcare emergencies.

19 June 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MMMiguel Martin
Miguel Martin
Julio de la Torre-MonteroJulio de la Torre-Montero
Julio de la Torre-Montero
SLSara López-Taruella
Sara López-Taruella
KPK. Pinilla
K. Pinilla
ACA. Casado
A. Casado
ALA. Lluch
A. Lluch
Background: Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. Patients and methods: BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1.5 to 5 years following primary diagnosis searching for PA. A confirmatory prevalence study was later performed in other two institutions. Finally, a prevention study using prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps in patients receiving adjuvant docetaxel was performed. Results: In the initial prevalence study (492 patients), minor forms of PA (grade 1) were recorded with all chemotherapy regimens and aromatase inhibitors. Patients receiving docetaxel regimens at cumulative dose (CD) ≥ 400 mmg/m2 presented a significantly higher prevalence of grades 1 PA (33–52%) and 2 PA (5–12%). Prevalence of grade 2 PA with docetaxel CD ≥ 400 mmg/m2 was confirmed in two other institutions. Overall, grade 2 PA was seen in 10.06% (95% CI 7.36–13.61) of 358 patients with docetaxel regimens reaching CD ≥ 400 mmg/m2, but not in patients with lower docetaxel CD, other chemotherapy regimens, or endocrine therapy alone. In prevention trial, no grade 2 PA occurred among 116 patients receiving adjuvant docetaxel (≥ 400 mmg/m2) and PSC followed-up after a 96 months median time. PSC was well tolerated. No scalp relapses were seen among 30 patients (22% of all inclusions) having disease relapse. Conclusion: Adjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762.

19 July 2013 in The Oncologist
Verified
Journal Article
Open access
PDF file
MMMiguel Martin
Miguel Martin
SCSara Custodio
Sara Custodio
MCMaria-Luisa Maestro Casas
Maria-Luisa Maestro Casas
JGJosé Ángel García-Saénz
José Ángel García-Saénz
Julio de la Torre-MonteroJulio de la Torre-Montero
Julio de la Torre-Montero
EDEduardo Díaz-Rubio
Eduardo Díaz-Rubio
Learning Objectives: Explain the prognostic value of baseline CTCs. Describe the predictive value of CTCs at day 21 after chemotherapy. Explain the meaning of the change of CTCs from baseline to day 21 after chemotherapy.

2 November 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ARAtocha Romero
Atocha Romero
MMM. Martín
M. Martín
BOB. Oliva
B. Oliva
Julio de la Torre-MonteroJulio de la Torre-Montero
Julio de la Torre-Montero
VFV. Furio
V. Furio
TCT. Caldés
T. Caldés
Identification of predicting factors for anthracyclines-based chemotherapy remains a clinical challenge. Glutathione S-transferase (GSTs) enzymes detoxify chemotherapy drugs and their metabolites. Several polymorphisms in GST genes result in reduced or no activity of the enzymes. Specifically, GSTM1 and GSTT1 genes are polymorphically deleted, the polymorphism GSTP1 c.313A > G (rs1695) determines the amino acid substitution Ile105Val, where the Val-containing enzyme has reduced activity. Also, GSTA1*B allele has reduced levels of GSTA1 enzyme. Several polymorphisms in GSTs have been associated with differences in survival for cancer patients treated with chemotherapy. We genotyped a total of five polymorphisms in GSTM1, GSTT1, GSTP1 and GSTA1 genes in 159 patients with locally advanced breast cancer, treated with single-agent doxorubicin or docetaxel (Taxotere). Gene expression microarrays were performed in 67 breast tumor samples. We correlate this data with treatment outcome. In multivariate analysis, patients homozygous GG for GSTP1 c.313A > G SNP had a lower risk of chemoresistance when treated with doxorubicin (odds ratio 0.106; confidence interval 0.012–0.898; P = 0.040). No association was found in the docetaxel arm. Also, we found that GSTP1 expression varied significantly among breast cancer molecular subtypes. GSTP1 may constitute another tool contributing to individualized anthracycline-based therapy.